At 11:00 am ET today (November 2, 2021), the results will be released for research that analyzed the effectiveness of the Johnson & Johnson vaccine for preventing COVID-19. The study will be published in JAMA Network Open, a monthly open access medical journal published by the American Medical Association.
What The Study Did: The findings of this study, which included 8,889 patients who received a single dose of the Ad26.COV2.S (Johnson & Johnson) COVID-19 vaccine and 88,898 unvaccinated patients, are consistent with the clinical trial–reported efficacy of Ad26.COV2.S, suggesting that the vaccine is effective at reducing SARS-CoV-2 infection, even with the spread of variants such as Alpha or Delta that were not present in the original studies, and reaffirm the urgent need to continue mass vaccination efforts globally.
Authors: Tyler Wagner, Ph.D., and Venky Soundararajan, Ph.D., of nference in Cambridge, Massachusetts, are the corresponding authors.
In the study, the incidence rate of SARS-CoV-2 infection was 60 out of 8889 vaccinated patients vs 2236 of 88,898 unvaccinated individuals. This corresponds to an effectiveness of 73.6%, incidence rate ratio of 0.26, and a 3.73-fold reduction in SARS-CoV-2 infections.
Link: JAMA Network Open
Reference: “Analysis of the Effectiveness of the Ad26.COV2.S Adenoviral Vector Vaccine for Preventing COVID-19” by Juan Corchado-Garcia, PhD; David Zemmour, MD, PhD; Travis Hughes, MD, PhD; Hari Bandi, PhD; Tudor Cristea-Platon, PhD; Patrick Lenehan, BS; Colin Pawlowski, PhD; Sairam Bade, BS; John C. O’Horo, MD; Gregory J. Gores, MD; Amy W. Williams, MD; Andrew D. Badley, MD; John Halamka, MD; Abinash Virk, MD; Melanie D. Swift, MD, MPH; Tyler Wagner, PhD and Venky Soundararajan, PhD, 2 November 2021, JAMA Network Open.
DOI: 10.1001/jamanetworkopen.2021.32540
Never miss a breakthrough: Join the SciTechDaily newsletter.
Follow us on Google and Google News.
5 Comments
How about citing the source of your claim that “… the most populated state in India just declared they are officially COVID free after promoting widespread use of the safe, proven medicine.”, instead of providing a site advertising the sale of the medicine claimed to be responsible!
The claim would be more believable if a verifiable high use-rate was provided, instead of the nebulous “widespread use.” It would seem that you are just trying to profit from the misfortune and fear of others. That is despicable!
Even so, India is not a typical G20 country. Hygiene leaves a lot to be desired with cows running around loose, relieving themselves everywhere, and potable water is often tainted with arsenic, if not pathogens. I would suspect that those with weak immune systems are quickly weeded out of the population, and may have already died before the “widespread use” of ivermectin.
It would seem that someone is just trying to profit from the
Nobody is profiting more than the pharmaceutical companies though….
And somehow the huge VA study of 800,000 just published in SCIENCE found that the J&J was close to useless (13% effective!) at preventing infection from Feb-Oct 2021.
And no conflicts of interest to speak of 😉
Conflict of Interest Disclosures: Dr Corchado-Garcia reported receiving personal fees from and holding stock in nference Inc outside the submitted work. Dr Zemmour reported receiving personal fees from nference Inc outside the submitted work. Dr Hughes reported receiving personal fees from nference Inc during the conduct of the study; and personal fees from nference Inc outside the submitted work. Mr Lenehan reported receiving other fees from Janssen (nference collaborates with Janssen on data science projects unrelated to this manuscript, and this relationship did not impact the study design or interpretation of its results) outside the submitted work. Dr Pawlowski reported receiving personal fees from nference Inc outside the submitted work. Dr O’Horo reported receiving personal fees from Elsevier and Bates College; and grants from nference Inc, outside the submitted work. Dr Badley reported being a consultant for AbbVie and Gilead; serving on scientific advisory boards for Freedom Tunnel, Pinetree Therapeutics, Primmune, Immunome, Flambeau Diagnostics, nference, and Zentalis; serving on data safety and monitoring boards for Corvus, Equillium, and Excision Biotherapeutics; and being founder and president of Splissen Therapeutics. Dr Virk reported being an inventor for Mayo Clinic Travel App interaction with Smart Medical Kit and Medical Kit for Pilgrims. Dr Swift reported receiving grants from Pfizer during the conduct of the study. Dr Wagner reported receiving personal fees from and holding stock in nference Inc outside the submitted work. Dr Soundararajan reported other from Janssen (nference collaborates with Janssen and other biopharmaceutical companies on data science initiatives unrelated to this study, and these collaborations had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript outside the submitted work. The Mayo Clinic may stand to gain financially from the successful outcome of this research. This research has been reviewed by the Mayo Clinic Conflict of Interest Review Board and was in compliance with Mayo Clinic Conflict of Interest policies. No other disclosures were reported.
I hope future generations can iron out the legalities involved in the prosecution of influencers when lives are the cost of lies.